← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
  1. Home
  2. Financial Ratios

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.
US Stock Screener
HomeScreensNewsWatchlist
...
  1. Home
  2. CLX
  3. Financial Ratios
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

The Clorox Company (CLX) Financial Ratios

30 years of historical data (1996–2025) · Consumer Defensive · Household & Personal Products

View Quarterly Ratios →

P/E Ratio
↓
19.50
↓-65% vs avg
5yr avg: 56.33
033%ile100
30Y Low9.1·High132.5
View P/E History →
EV/EBITDA
↓
13.83
↓-24% vs avg
5yr avg: 18.14
063%ile100
30Y Low8.8·High22.2
P/FCF
↓
21.85
↓-18% vs avg
5yr avg: 26.60
060%ile100
30Y Low13.2·High152.0
P/B Ratio
↓
32.79
-8% vs avg
5yr avg: 35.83
058%ile100
30Y Low4.3·High117.0
ROE
↑
166.3%
↓+97% vs avg
5yr avg: 84.3%
077%ile100
30Y Low17%·High426%
Debt/EBITDA
↓
2.06
↓-20% vs avg
5yr avg: 2.58
050%ile100
30Y Low0.7·High3.4

Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.

Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

The Clorox Company trades at 19.5x earnings, 65% below its 5-year average of 56.3x, sitting at the 33rd percentile of its historical range. Compared to the Consumer Defensive sector median P/E of 21.6x, the stock trades at a discount of 10%. On a free-cash-flow basis, the stock trades at 21.8x P/FCF, 18% below the 5-year average of 26.6x.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$16.6B$14.9B$17.0B$19.7B$17.5B$22.9B$28.0B$19.9B$17.8B$17.5B$18.2B
Enterprise Value$19.3B$17.6B$19.7B$22.3B$20.4B$25.7B$30.3B$22.4B$20.1B$19.3B$20.1B
P/E Ratio →19.5018.4260.65132.5337.8032.2429.8524.2321.6425.0028.13
P/S Ratio2.342.102.402.672.463.124.173.202.912.933.16
P/B Ratio32.7930.9634.6250.9023.9638.6930.8435.5524.5132.3461.37
P/FCF21.8519.6135.2621.2432.6524.2421.6825.2822.8227.5230.08
P/OCF16.9515.2124.5117.0622.2217.9518.1220.0318.2720.2023.43

P/E links to full P/E history page with 30-year chart

EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

The Clorox Company's enterprise value stands at 13.8x EBITDA, 24% below its 5-year average of 18.1x. The Consumer Defensive sector median is 12.3x, placing the stock at a 12% premium on an enterprise-value basis.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—2.482.783.022.873.514.503.613.293.233.50
EV / EBITDA13.8312.6217.1420.9822.1617.7820.9517.4115.5915.0216.33
EV / EBIT16.4014.9639.3965.4228.9625.9323.6820.1317.9117.3218.91
EV / FCF—23.1740.8623.9938.1127.2523.4228.5625.8330.3133.23

Profitability

Margins and return-on-capital ratios measuring operating efficiency

The Clorox Company earns an operating margin of 16.6%, significantly above the Consumer Defensive sector average of 1.1%. Operating margins have expanded from 11.2% to 16.6% over the past 3 years, signaling improving operational efficiency. Return on equity of 166.3% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks — well above the sector median of 7.8%. ROIC of 27.7% represents excellent returns on invested capital versus a sector median of 5.7%.

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin45.0%45.0%42.6%38.9%35.0%43.3%45.4%43.6%43.5%44.6%45.2%
Operating Margin16.6%16.6%12.9%11.2%9.8%16.9%18.8%17.8%18.4%18.8%18.5%
Net Profit Margin11.4%11.4%3.9%2.0%6.5%9.7%14.0%13.2%13.4%11.7%11.2%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE166.3%166.3%63.6%26.7%69.9%94.7%128.0%127.6%129.8%167.1%312.3%
ROA14.3%14.3%4.8%2.5%7.4%11.3%16.6%16.1%17.1%15.4%14.9%
ROIC27.7%27.7%22.4%18.8%14.7%28.1%30.2%26.7%31.3%37.2%38.7%
ROCE30.2%30.2%22.3%19.7%16.1%27.3%29.9%29.4%34.0%39.2%37.3%

Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

The Clorox Company carries a Debt/EBITDA ratio of 2.1x, which is manageable (36% below the sector average of 3.2x). Net debt stands at $2.7B ($2.9B total debt minus $167M cash). Interest coverage of 11.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity5.985.985.907.544.265.353.444.803.424.057.78
Debt / EBITDA2.062.062.522.753.372.192.162.081.921.711.88
Net Debt / Equity—5.635.496.594.014.812.484.603.243.286.43
Net Debt / EBITDA1.941.942.352.413.171.971.562.001.821.381.55
Debt / FCF—3.575.592.755.463.011.743.273.022.793.15
Interest Coverage11.6711.678.898.037.1813.3113.6012.1614.2413.6813.02

Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

The current ratio of 0.84x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.95x to 0.84x over the past 3 years.

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.840.841.030.950.970.891.420.911.090.840.95
Quick Ratio0.570.570.630.590.540.521.100.550.670.580.67
Cash Ratio0.090.090.130.190.100.160.610.080.110.230.26
Asset Turnover—1.281.231.241.151.161.081.211.211.311.28
Inventory Turnover7.487.486.396.496.115.538.086.846.847.207.13
Days Sales Outstanding—42.1835.7633.9934.9730.0335.1937.0635.7634.5336.05

Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

The Clorox Company returns 5.8% to shareholders annually — split between a 3.8% dividend yield and 2.0% buyback yield. The payout ratio of 74.3% is elevated — while still covered by earnings, there is limited headroom for dividend increases. The earnings yield of 5.1% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield3.8%4.0%3.5%3.0%3.3%2.4%1.9%2.5%2.5%2.4%2.2%
Payout Ratio74.3%74.3%212.5%391.3%123.6%78.6%56.8%59.8%54.7%58.8%61.4%

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield5.1%5.4%1.6%0.8%2.6%3.1%3.4%4.1%4.6%4.0%3.6%
FCF Yield4.6%5.1%2.8%4.7%3.1%4.1%4.6%4.0%4.4%3.6%3.3%
Buyback Yield2.0%2.2%0.0%0.0%0.1%4.0%0.9%3.3%1.5%1.0%1.4%
Total Shareholder Yield5.8%6.3%3.5%3.0%3.4%6.4%2.8%5.8%4.1%3.4%3.6%
Shares Outstanding—$124M$125M$124M$124M$127M$128M$130M$132M$132M$132M

Peer Comparison

Compare CLX with 5 similar companies in its peer group

CompanyMarket CapP/EEV/EBITDAP/FCFGross MarginOp MarginROEROICDebt/EBITDA
CLXYou$17B19.513.821.845.0%16.6%166.3%27.7%2.1
PG$389B25.717.827.751.2%24.3%31.1%20.1%1.5
UL$161B27.314.417.6100.0%15.5%26.5%15.3%2.7
KMB$37B18.414.022.635.6%14.5%147.9%23.2%2.3
CHD$25B34.720.122.744.7%17.4%17.6%13.9%1.7
TANH$932178-0.1-5.30.220.8%9.3%-2.6%3.0%0.8
Consumer Defensive Median—21.612.316.440.7%1.1%7.8%5.7%3.2

Peers based on L4 peer group classification. Compare multiple stocks →

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

See CLX's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is CLX Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare CLX vs PG

See how CLX stacks up against sector leader The Procter & Gamble Company.

Start Comparison

Frequently Asked Questions

What is The Clorox Company's P/E ratio?

The Clorox Company's current P/E ratio is 19.5x. The historical average is 32.9x. This places it at the 33th percentile of its historical range.

What is The Clorox Company's EV/EBITDA?

The Clorox Company's current EV/EBITDA is 13.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.6x.

What is The Clorox Company's ROE?

The Clorox Company's return on equity (ROE) is 166.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 115.9%.

Is CLX stock overvalued?

Based on historical data, The Clorox Company is trading at a P/E of 19.5x. This is at the 33th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What is The Clorox Company's dividend yield?

The Clorox Company's current dividend yield is 3.81% with a payout ratio of 74.3%.

What are The Clorox Company's profit margins?

The Clorox Company has 45.0% gross margin and 16.6% operating margin. Operating margin between 10-20% is typical for established companies.

How much debt does The Clorox Company have?

The Clorox Company's Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.